The fourteenth report on survey of adverse reaction to radiopharmaceuticals

This report deals with adverse reactions to radiopharmaceuticals occurring during the period from April 1, 1991 through March 31, 1992. Questionnaires were sent to 1,150 facilities, and 906 (78.8%) responded. Twenty one cases of adverse reactions and 7 cases of drug defects were reported from a total of 19 facilities (2.1%), giving an annual incidence of 2.0 and 0.7 cases, respectively, for 100,000 administered cases. The ratio of the occurrence in the 17th survey to that in the 16th survey was 1.18 for adverse reactions and 0.39 for drug defects. The occurrence of drug defects in this survey was lowest compared with that in the previous five surveys. According to radiopharmaceuticals, the incidence of adverse reactions was as follows: I-131-6β-iodomethyl-19-norcholesterol>I-123 orthoiodohippurate>I-131 orthoiodohippurate>Tc-99m DMSA>Tc-99m DTPA>Tc-99m MAA>Ga-67 citrate>Tc-99m MDP>Tc-99m HMDP. Adverse reactions included reactions to the vagus nerves (n=9), allergic reactions (n=3), and others (n=9). Radiopharmaceuticals reported as drug defects were as follows: Tc-99m pertechnetate, Tc-99m MDP, Tc-99m HMDP, Tc-99m phytate, and Tl-201 chloride. (N.K.)